Surgical robotics company Transenterix Inc. reported a larger-than-expected loss in the second quarter, causing its stock to drop 6.6 percent in Tuesday trading.

The Research Triangle Park-based company reported a net loss of $34.2 million, or 17 cents per share, compared to a net loss of $14.7 million, or 11 cents per share, in the same quarter a year ago.

Analysts were expected a loss of 6 cents per share.

The company reported revenue of $6.4 million in the quarter, higher than the expected $5.78 million expected by analysts. Revenue in the quarter a year ago was $1.6 million.

“Our performance during the second quarter was solid as we continued to drive system sales both in the U.S. and abroad, while simultaneously making significant progress towards our 2018 goals, including the expansion of Senhance’s indications for use and broadening our portfolio of instruments,” said Chief Executive Officer Todd Pope in a statement.

Transenterix stock fell 36 cents to $5.03 in Tuesday morning trading. It has been as low as $4.70.

The company sold four of its Senhance systems in the quarter — one in the United States and three in the Europe, Middle East and Africa region.

On May 29, the company received U.S. Food and Drug Administration clearance of its Senhance system for laparoscopic inguinal hernia and laparoscopic gallbladder removal surgery.

There are approximately 760,000 inguinal hernia and 1.2 million laparoscopic gallbladder removal procedures performed annually in the U.S.

On June 7, the company announced that it had filed an FDA submission for additional Senhance system instruments, including 3 millimeter diameter instruments.